Spots Global Cancer Trial Database for nkg2d
Every month we try and update this database with for nkg2d cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | NCT05583201 | Gastric Cancer Pancreatic Canc... Solid Tumor | KD-496 | 18 Years - 75 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | NCT05213195 | Refractory Meta... | NKG2D CAR-NK | 18 Years - 70 Years | Zhejiang University | |
| NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | NCT05583201 | Gastric Cancer Pancreatic Canc... Solid Tumor | KD-496 | 18 Years - 75 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | NCT05462873 | Carcinoma, Non-... Carcinoma, Rena... Esophageal Squa... Squamous Cell C... | QEQ278 | 18 Years - | Novartis | |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | NCT02203825 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CM-CS1 T-cell i... | 18 Years - | Celyad Oncology SA | |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | NCT02203825 | Acute Myeloid L... Myelodysplastic... Multiple Myelom... | CM-CS1 T-cell i... | 18 Years - | Celyad Oncology SA | |
| NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer | NCT05248048 | Refractory Meta... | CAR-T infusion | 18 Years - 75 Years | The Third Affiliated Hospital of Guangzhou Medical University | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | NCT05213195 | Refractory Meta... | NKG2D CAR-NK | 18 Years - 70 Years | Zhejiang University | |
| NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | NCT05583201 | Gastric Cancer Pancreatic Canc... Solid Tumor | KD-496 | 18 Years - 75 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | NCT04658004 | Acute Myeloid L... | NKG2D CAR T-cel... | 3 Years - 70 Years | Zhejiang University | |
| NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | NCT05382377 | CRC Solid Tumor | KD-025 | 18 Years - 70 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
